AU2003217430B2 - Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists - Google Patents

Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists Download PDF

Info

Publication number
AU2003217430B2
AU2003217430B2 AU2003217430A AU2003217430A AU2003217430B2 AU 2003217430 B2 AU2003217430 B2 AU 2003217430B2 AU 2003217430 A AU2003217430 A AU 2003217430A AU 2003217430 A AU2003217430 A AU 2003217430A AU 2003217430 B2 AU2003217430 B2 AU 2003217430B2
Authority
AU
Australia
Prior art keywords
dopamine
disorders
compound
pharmaceutical composition
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003217430A
Other languages
English (en)
Other versions
AU2003217430A1 (en
Inventor
Durk Dijkstra
Hakan Wikstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darpharma Inc
Original Assignee
Darpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/xx
Priority claimed from SE0200474A external-priority patent/SE0200474D0/xx
Application filed by Darpharma Inc filed Critical Darpharma Inc
Publication of AU2003217430A1 publication Critical patent/AU2003217430A1/en
Application granted granted Critical
Publication of AU2003217430B2 publication Critical patent/AU2003217430B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003217430A 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists Ceased AU2003217430B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (sv) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200478-6 2002-02-15
SE0200474A SE0200474D0 (sv) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline
SE0200474-5 2002-02-17
PCT/US2003/004592 WO2003070245A1 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists

Publications (2)

Publication Number Publication Date
AU2003217430A1 AU2003217430A1 (en) 2003-09-09
AU2003217430B2 true AU2003217430B2 (en) 2008-10-23

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003217430A Ceased AU2003217430B2 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists

Country Status (11)

Country Link
US (1) US7220754B2 (enExample)
EP (1) EP1480647B1 (enExample)
JP (1) JP2005526728A (enExample)
AT (1) ATE406896T1 (enExample)
AU (1) AU2003217430B2 (enExample)
CA (1) CA2476115A1 (enExample)
DE (1) DE60323339D1 (enExample)
DK (1) DK1480647T3 (enExample)
ES (1) ES2314189T3 (enExample)
NO (1) NO20043634L (enExample)
WO (1) WO2003070245A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
CN1964713A (zh) * 2003-12-23 2007-05-16 达法尔摩公司 多巴胺－受体结合化合物的共同使用
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
EP2010541A2 (en) * 2006-02-21 2009-01-07 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
WO2014072881A1 (en) * 2012-11-08 2014-05-15 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282227A (en) 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US4340600A (en) 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
DE69334206D1 (de) * 1992-05-26 2008-04-03 Purdue Research Foundation Substituierte hexahydrobenzo(a) phenanthridine
PT690863E (pt) 1993-04-06 2003-07-31 Abbott Lab Compostos tetraciclicos como agonistas da dopamina
WO1996002513A1 (en) 1994-07-15 1996-02-01 Purdue Research Foundation Optically active isomers of dihydrexidine and its substituted analogs
PT845988E (pt) 1995-08-18 2002-05-31 Univ North Carolina Novas isoquinolinas fundidas como ligandos do receptor da dopamina

Also Published As

Publication number Publication date
EP1480647A4 (en) 2005-07-13
WO2003070245A1 (en) 2003-08-28
ES2314189T3 (es) 2009-03-16
JP2005526728A (ja) 2005-09-08
DK1480647T3 (da) 2009-01-26
AU2003217430A1 (en) 2003-09-09
DE60323339D1 (de) 2008-10-16
EP1480647B1 (en) 2008-09-03
WO2003070245B1 (en) 2004-05-27
CA2476115A1 (en) 2003-08-28
ATE406896T1 (de) 2008-09-15
EP1480647A1 (en) 2004-12-01
US20050096469A1 (en) 2005-05-05
NO20043634L (no) 2004-11-11
US7220754B2 (en) 2007-05-22

Similar Documents

Publication Publication Date Title
DE69426376T2 (de) Substituierte Azepino (2,1-a)isochinolin Verbindungen
DE60126132T2 (de) Lactamverbindung zur hemmung der freisetzung oder der synthese von beta-amyloidpeptid
JP3812952B2 (ja) シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
US5109008A (en) Pharmaceutically useful furo[3,2-c]pyridines
DE69432217T2 (de) Tetracyclische verbindungen als dopamin-agonisten
JPH01308250A (ja) ピペリジン誘導体
BE898278A (fr) Benzoxazines antipsychotiques.
DE60118195T2 (de) Modulatoren von protein tyrosin phosphatasen (ptpasen)
US20250268883A1 (en) Therapeutic methods and compositions for treating movement disorders
EP1480647B1 (en) Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
DE69628360T2 (de) Azepinonverbindungen zur Anwendung bei der Hemmung von ACE und NEP
DE69919349T2 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
AU2013257706A1 (en) Compositions and methods for the treatment of neurological disorders
CN113087713B (zh) 一类苯并二氮䓬衍生物及其制备方法和用途
US5668141A (en) Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists
US4923863A (en) Morpholine derivatives, pharmaceutical compositions and use
US6046200A (en) Compositions having neuroprotective and analgesic activity
EP2421862B1 (en) Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
AU2004212328A1 (en) Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
CA2643300C (en) Trans-fused chromenoisoquinolines, synthesis and methods for use
US5114945A (en) Spiropiperidine derivatives
EP0003286B1 (de) Ergopeptidalkaloid-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US5955493A (en) Thiamorphinans with neuroprotective activity
US4870080A (en) Polyhydro derivatives of 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
US20260124147A1 (en) Therapeutic methods and compositions for treating movement disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired